China 
Africa 
Explore chapters and articles related to this topic
Drug profiles: generic names A–Z
Published in Jerome Z. Litt, Neil H. Shear, Litt's Drug Eruption & Reaction Manual, 2017
Note: Atripla is tenofovir disoproxil, efavirenz and emtricitabine; Complera is tenofovir disoproxil, emtricitabine and rilpivirine; Truvada is tenofovir disoproxil and emtricitabine. See also separate profile for tenofovir disoproxil in combination with cobicistat, elvitegravir and emtricitabine.
Drug profiles: generic names A-Z
Published in Jerome Z. Litt, Neil H. Shear, Litt's Drug Eruption & Reaction Manual, 2017
Note: Atripla is tenofovir disoproxil, efavirenz and emtricitabine; Complera is tenofovir disoproxil, emtricitabine and rilpivirine; Truvada is tenofovir disoproxil and emtricitabine. See also separate profile for tenofovir disoproxil in combination with cobicistat, elvitegravir and emtricitabine.
Awareness, acceptability, and intention to initiate HIV pre-exposure prophylaxis among pregnant women
Published in AIDS Care, 2022
Rachel K. Scott, Shawnika J. Hull, Robin C. Richards, Kristen Klemmer, Frida Salmoran, Jim C. Huang
HIV pre-exposure prophylaxis (PrEP) with daily oral tenofovir disoproxil fumarate/emtricitabine reduces HIV acquisition by up to 92% when adherence is high (Baeten et al., 2012; Murnane et al., 2013; Thigpen et al., 2012). The most recent guidelines from the American College of Obstetricians and Gynecologists and the World Health Organization offer consensus that all viable prevention options should be made available to women at risk for HIV, including during pregnancy and lactation (Committee on Gynecologic Practices, 2014; WHO, 2017). Tenofovir disoproxil fumarate/emtricitabine has been shown to be safe (for both treatment and prevention of HIV) (AIDSinfo, n.d.; Flynn et al., 2011; Heffron et al., 2016; Heffron et al., 2017, 2018; Joseph Davey et al., 2020; Kourtis et al., 2018; Mirochnick et al., 2014; Mofenson et al., 2017; Nachega et al., 2017; Pintye et al., 2017; Salvadori et al., 2018) during pregnancy, however, PrEP remains underutilized.
Prevalence of kidney injury in patients taking tenofovir based antiretroviral therapy at a primary health care clinic, in East Rand,Gauteng Province
Published in Hospital Practice, 2021
P Makamu, S Bezuidenhout, M Matlala
Amongst all the drugs that have been approved for the treatment of HIV infection across the globe, Tenofovir Disoproxil Fumarate (TDF) remains the most preferred drug of choice to be part of the antiretroviral (ARV) regimen due to its efficacy and tolerability [4,5]. Tenofovir disoproxil fumarate is currently one of the key medicines in the management of HIV infection in SA. As part of the first-line ART treatment regimen, TDF is conveniently formulated in a fixed-dose combination (FDC), thus reducing pill burden and improving patient compliance [6,7]. Tenofovir disoproxil fumarate is also recommended in HIV prevention programs for post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) for individuals at a substantial risk of acquiring HIV infection [8,9]. Although clinical trial data indicate a low incidence of serious renal dysfunction, studies found a correlation between TDF use and a decline in the estimated glomerular filtration rate (eGFR), proximal tubular dysfunction, proteinuria, chronic kidney disease (CKD), and increased mortality [10,11].
Incapacitating pain from Tenofovir Induced Hypophosphatemic Osteomalacia in a Hemophilia Patient – A Case Report
Published in Canadian Journal of Pain, 2020
Emma Woo, Dinesh Kumbhare, Paul Winston
Pain is commonplace in patients with hemophilia and often arises as the result of hemarthrosis, joint bleeds that may cause progressive joint damage and have a significant effect on quality of life and mobility.1 However, it cannot be assumed that severe pain is due to hemarthrosis-related joint damage. Clinicians should consider a wide range of etiologies for pain in patients with hemophilia. Acute causes include infection, osteoporotic fractures, bleeds, with chronic causes including arthritis, and osteomalacia. A comprehensive medical history may reveal unanticipated causes, including side effects from medications such as tenofovir, specifically tenofovir disoproxil fumarate. This case demonstrates a rare instance of poorly localized back and hip pain, severe enough to prevent ambulation in a patient with hemophilia A caused by hypophosphatemic osteomalacia due to tenofovir treatment for blood transfusion–acquired human immunodeficiency virus (HIV). In the early 1980s, before blood products were tested or heated, nearly 50% of the U.S. population with hemophilia had become infected with HIV from blood transfusions.2 Among the aging population of people with hemophilia, there is a significant likelihood of an HIV infection.2 Other uses of tenofovir include pre-exposure prophylaxis (PrEP) and treatment of chronic hepatitis B infections.